MAT
49
3
GOOGL
72
-3
GWW
57
4
NRG
77
2
FLS
55
3
TGNA
48
6
HP
34
4
MET
38
-6
GT
54
7
NTAP
68
6
LLY
56
3
PXD
50
4
MOS
29
6
VLO
35
5
FMC
40
3
ABBV
42
2
ACN
33
-3
WRK
65
9
TMO
63
3
STZ
73
3
MAT
49
3
GOOGL
72
-3
GWW
57
4
NRG
77
2
FLS
55
3
TGNA
48
6
HP
34
4
MET
38
-6
GT
54
7
NTAP
68
6
LLY
56
3
PXD
50
4
MOS
29
6
VLO
35
5
FMC
40
3
ABBV
42
2
ACN
33
-3
WRK
65
9
TMO
63
3
STZ
73
3
Financhill
Back

UroGen Pharma 10K Form

Buy
53

URGN
UroGen Pharma

Last Price:
13.93
Seasonality Move:
-7.76%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-14 10Q URGN/UroGen Pharma Quarterly
2023-08-10 10Q URGN/UroGen Pharma Quarterly
2023-05-11 10Q URGN/UroGen Pharma Quarterly
2022-11-10 10Q URGN/UroGen Pharma Quarterly
2022-08-11 10Q URGN/UroGen Pharma Quarterly
2022-05-10 10Q URGN/UroGen Pharma Quarterly

Receive URGN News And Ratings

See the #1 stock for the next 7 days that we like better than URGN

URGN Financial Statistics

Sales & Book Value

Annual Sales: $82.71M
Cash Flow: $-13.05M
Price / Cash Flow: 0
Annual Sales: $-2.01
Price / Book: 0

Profitability

EPS (TTM): -3.67000
Net Income (TTM): $-102.24M
Gross Margin: $73.35M
Return on Equity: 0%
Return on Assets: -71.41%

UroGen Pharma Earnings Forecast

Key UroGen Pharma Financial Ratios

  • The Gross Profit Margin over the past 9 years for URGN is 88.68%.
  • The Selling, General & Administrative Expenses for URGN have been equal to 112.77% of Gross Profit Margin.
  • The Research & Development expenses have been 55.15% of Revenue.
  • The Interest Expense is -14.39% of Operating Income.
  • The Net Earning history of URGN is -123.61% of Total Revenues.
  • Per Share Earnings over the last 9 years have been positive in 4 years.

UroGen Pharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: URGN
CUSIP: M96088
Website: urogen.com

Debt

Debt-to-Equity Ratio: -1.51
Current Ratio: 5.42
Quick Ratio: 4.88

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

URGN Technical Analysis vs Fundamental Analysis

Buy
53
UroGen Pharma (URGN) is a Buy

Is UroGen Pharma a Buy or a Sell?

  • UroGen Pharma stock is rated a Buy
    The current UroGen Pharma [URGN] share price is $14.04. The Score for URGN is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.